For my opinion of today’s “trading” of IPIX SP please reread my post # 68049. Criminally controlled share price and phony volume. Rinse and repeat.
The following are a couple of examples from 2019 IPIX PR’s and Updates. At the time of these PR’s the paid bashers called these “fluff” PR’s. If you look at the significance of these PRs you will understand that Leo has been strategically laying out a long term plan for Brilacidin for years. The current CV19 human trial is only the very beginning of monetizing the Brialcidin asset.
If you read the Update that is linked to the 10/8/19 PR (Months before anyone in the U.S. was aware of the CV19 virus) you will notice a Brilacidin diagram that lists major design benefits of Brilacidin including its direct antimicrobial properties to treat bacterial , fungal, parasitic and viral disease. Examples listed at that time of this update includes treatment of viral disease including influenza , herpes and RSV. In addition to the antimicrobial properties the diagram also shows design properties with antibiofilm activity and immunomodulatory activity including anti- inflammatory and adjuvanticity.
Two years ago the 2/26/19 IPIX PR announced the establishment of an IPIX Irish Subsidiary to facilitate engagement with European Medicines Agency (EMA). The checker players all scratched their heads. The chess player was playing the long game.
October 8, 2019
Brilacidin’s Development as an HDP-Mimetic in Context
An arylamide foldamer and unlike peptidic-based small molecules, Brilacidin is not subject to traditional shortcomings of peptide-based compounds (e.g., rapid proteolytic degradation, toxicity and tissue distribution concerns, cost of manufacturing, etc.), which have limited development prospects. Instead, by using sophisticated coarse grain computer modeling that mimicked the actions of natural defensins (electrostatics, lipophicility), Brilacidin was designed (pdf) de novo—originally by University of Pennsylvania-based researchers, including two National Academy of Science members: William DeGrado and Michael Klein—to be smaller (one-tenth the size) and then further fine-tuned to exhibit enhanced pharmacological properties. This made the drug candidate more easily and much less expensively synthesized; more stable (a rigid backbone and sidechains); more potent; and more selective . Biocomputational aspects of Brilacidin’s development have resulted in the drug candidate exhibiting more tailored exposure and efficacy.
Innovation Pharmaceuticals Cites Recent Academic Literature Showing Host Defense Proteins at Cutting-Edge of Medicine for Multiple Diseases — Innovation Pharmaceuticals Inc. (ipharminc.com)
http://www.ipharminc.com/new-blog/2019/10/8/l...brilacidin
Innovation Pharmaceuticals Forms Irish Subsidiary to Facilitate International Development of Clinical Pipeline — Innovation Pharmaceuticals Inc. (ipharminc.com)
The following are a couple of examples from 2019 IPIX PR’s and Updates. At the time of these PR’s the paid bashers called these “fluff” PR’s. If you look at the significance of these PRs you will understand that Leo has been strategically laying out a long term plan for Brilacidin for years. The current CV19 human trial is only the very beginning of monetizing the Brialcidin asset.
If you read the Update that is linked to the 10/8/19 PR (Months before anyone in the U.S. was aware of the CV19 virus) you will notice a Brilacidin diagram that lists major design benefits of Brilacidin including its direct antimicrobial properties to treat bacterial , fungal, parasitic and viral disease. Examples listed at that time of this update includes treatment of viral disease including influenza , herpes and RSV. In addition to the antimicrobial properties the diagram also shows design properties with antibiofilm activity and immunomodulatory activity including anti- inflammatory and adjuvanticity.
Two years ago the 2/26/19 IPIX PR announced the establishment of an IPIX Irish Subsidiary to facilitate engagement with European Medicines Agency (EMA). The checker players all scratched their heads. The chess player was playing the long game.
October 8, 2019
Brilacidin’s Development as an HDP-Mimetic in Context
An arylamide foldamer and unlike peptidic-based small molecules, Brilacidin is not subject to traditional shortcomings of peptide-based compounds (e.g., rapid proteolytic degradation, toxicity and tissue distribution concerns, cost of manufacturing, etc.), which have limited development prospects. Instead, by using sophisticated coarse grain computer modeling that mimicked the actions of natural defensins (electrostatics, lipophicility), Brilacidin was designed (pdf) de novo—originally by University of Pennsylvania-based researchers, including two National Academy of Science members: William DeGrado and Michael Klein—to be smaller (one-tenth the size) and then further fine-tuned to exhibit enhanced pharmacological properties. This made the drug candidate more easily and much less expensively synthesized; more stable (a rigid backbone and sidechains); more potent; and more selective . Biocomputational aspects of Brilacidin’s development have resulted in the drug candidate exhibiting more tailored exposure and efficacy.
Innovation Pharmaceuticals Cites Recent Academic Literature Showing Host Defense Proteins at Cutting-Edge of Medicine for Multiple Diseases — Innovation Pharmaceuticals Inc. (ipharminc.com)
http://www.ipharminc.com/new-blog/2019/10/8/l...brilacidin
Innovation Pharmaceuticals Forms Irish Subsidiary to Facilitate International Development of Clinical Pipeline — Innovation Pharmaceuticals Inc. (ipharminc.com)
17
